Skip to content

Protective Face Masks and Cardiopulmonary Parameters at Rest and During Exercise in Children

Effects of Protective Face Masks on Cardiopulmonary Parameters at Rest and During Exercise in Children

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05193422
Enrollment
40
Registered
2022-01-14
Start date
2022-01-20
Completion date
2022-03-20
Last updated
2022-01-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Exercise, Face-masks

Keywords

face-masks, exercise, children

Brief summary

This study will examine the possible effects of protective surgical masks on the cardiorespiratory function of children aged 8-14 years at rest and during exercise. The study will consist of two phases: * Phase I: No face mask. 1. Measurement of peak nasal inspiratory flow 2. CPET with an ergometric bike at 30% of their predicted maximum workload (Wmax) for 4 minutes, 50% of Wmax for 2 minutes and 70% of Wmax for 1 minute, with continuous oxygen saturation (SpΟ2), heart rate (HR), end-tidal CO2 (EtCO2) and respiratory rate (RR) monitoring. 3. Spirometry and measurement of nPIF immediately after CPET. 4. Discomfort assessment using a special scale * Phase II: Face mask. Following nPIF measurement, participants will be asked to wear a standard surgical face mask. A temperature and humidity sensor will also be placed inside the mask. Will follow: 1. Resting phase, 6 minutes. SpO2, HR, EtCO2 and RR will be monitored. 2. CPET at 30% of Wmax for 4 minutes, 50% Wmax for 2 minutes and 70% Wmax for 1 minute. SpO2, HR, EtCO2 and RR will be continuously monitored. 3. Spirometry and measurement of nPIF immediately after CPET. 4. Discomfort assessment. Both phases will be performed on the same day with a recovery phase of 30 minutes between them. Participants will be randomized to begin with Phase I followed by Phase II or Phase II followed by Phase I. At both phases, SpO2, HR, EtCO2 and RR (10 s average values) will be recorder at each 1 minute during CPET, and at minutes 0, 3 and 6 during the resting phase of Phase II. During Phase II, temperature and humidity will also be recorded at each 1 minute during CPET and at minutes 0, 3 and 6 during the resting phase. The total duration of the protocol is estimated at 90 minutes per participant. The study sample will consist of 40 children stratified by age.

Detailed description

PURPOSE The purpose of this study is to investigate the possible effects of protective surgical masks on the cardiorespiratory function of children aged 8-14 years at rest and during exercise. METHODS A. Population Children aged 8-14 years (minimum height 135 cm) will be invited to participate. They will be recruited from the outpatient clinics of the Pediatric Allergy and Pediatric Endocrinology Departments of the University Hospital of Patras, Greece. Children should not suffer from conditions that are likely to affect cardiopulmonary exercise testing (CPET) outcomes, such as respiratory (asthma and chronic lung disease), cardiac (congenital heart disease, heart failure), neurologic and musculoskeletal disorders. The parents of the children will be informed about the aims of the study and they will be asked to give written consent. The study has been approved by the local Research and Ethics Committee (Act no. 407/9.10.2020). B. Protocol The study will be performed at the Respiratory Functions and CPET Laboratory of the Pediatric Pulmonary Unit. Children will present to the laboratory with one of their parents. After history taking and measurement of weight and height, baseline spirometry will follow using a Micro5000 device (Medisoft, Sorinnes, Belgium) to determine FEV1, FVC, FEV1/FVC, FEF25-75 and PEF. The study will consist of two phases: * Phase I: No face mask. Participants will perform 1. Measurement of peak nasal inspiratory flow (nPIF) using the Micro5000 device and a specially modified nasal mask. 2. CPET using an ULTIMA CPX device (MGC Diagnostics, Saint Paul, MI, USA) with an ergometric bike (eBike, GE Healthcare, Wauwatosa, WI, USA). Participants will be asked to exercise (steady pedaling at 60 rpm) at 30% of their predicted maximum workload (Wmax) for 4 minutes, at 50% of Wmax for 2 minutes and at 70% of Wmax for 1 minute. Wmax will be calculated as 3 Watts/kg. During CPET, oxygen saturation (SpΟ2) and heart rate (HR) will be continuously monitored using a Nonin 7500 pulse oximeter with a special ear sensor (Nonin Medical Inc, Plymouth, MN, USA). End-tidal CO2 (EtCO2) and respiratory rate (RR) will also be monitored using a Microstream device with special sampling (nasal) lines (Medtronic, Minneapolis, MN, USA). 3. Spirometry and measurement of nPIF immediately after CPET. 4. Discomfort assessment using a special scale graded from 1 to 10. * Phase II: Face mask. Following nPIF measurement, participants will be asked to wear a standard surgical face mask. A temperature and humidity sensor (RHT03, MaxDetect Technologies, Shenzhen, China) will also be placed inside the mask on the right cheek, at nose level. Subsequently will follow: 1. Resting phase, with the participants on the ergometric bike without pedaling and breathing normally for 6 minutes. SpO2, HR, EtCO2 and RR will be monitored during the resting phase. 2. CPET at 30% of Wmax for 4 minutes, 50% of Wmax for 2 minutes and 70% of Wmax for 1 minute. SpO2, HR, EtCO2 and RR will be continuously monitored. 3. Spirometry and measurement of nPIF immediately after CPET. 4. Discomfort assessment. Both phases will be performed on the same day with a recovery phase of 30 minutes between them. Participants will be randomized to begin with Phase I followed by Phase II or Phase II followed by Phase I. At both phases, SpO2, HR, EtCO2 and RR (10 s average values) will be recorder at each 1 minute during CPET, and at minutes 0, 3 and 6 during the resting phase of Phase II. During Phase II, temperature and humidity will also be recorded at each 1 minute during CPET and at minutes 0, 3 and 6 during the resting phase. The total duration of the protocol is estimated at 90 minutes per participant. The study sample will consist of 40 children stratified by age.

Interventions

DIAGNOSTIC_TESTSpirometry - baseline

Standard spirometry using a Micro5000 spirometer to determine baseline FEV1, FVC, FEV1/FVC, FEF25-75 and PEF. Baseline spirometry will be performed before CPET in both study arms

DIAGNOSTIC_TESTSpirometry - post CPET

Standard spirometry using a Micro5000 spirometer to determine baseline % change in FEV1 after CPET and assess exercise-induced bronchoconstriction (defined as FEV1 decrease \>10% at 5 minutes after CPET) Post spirometry will be performed after CPET in both study arms

DIAGNOSTIC_TESTNasal peak inspiratory flow - baseline

Measurement of peak nasal inspiratory flow (nPIF) using a Micro5000 spirometer and a specially modified nasal mask. nPIF will be measured before CPET in both study arms

DIAGNOSTIC_TESTNasal peak inspiratory flow - post CPET

Measurement of peak nasal inspiratory flow (nPIF) using a Micro5000 spirometer and a specially modified nasal mask. nPIF will be measured after CPET in both study arms

DIAGNOSTIC_TESTOxygen saturation

Continuous monitoring of SpO2 using a Nonin 7500 pulse oximeter, in both study arms

DIAGNOSTIC_TESTHeart Rate

Continuous monitoring of HR using a Nonin 7500 pulse oximeter, in both study arms

DIAGNOSTIC_TESTEnd-tidal CO2

Continuous monitoring of EtCO2 using a Microstream capnograph, in both study arms

DIAGNOSTIC_TESTRespiratory rate

Continuous monitoring of RR using a Microstream capnograph, in both study arms

DIAGNOSTIC_TESTTemperature

Continuous monitoring of Temp in the face mask using a RHT03 sensor, only in the experimental study arm

DIAGNOSTIC_TESTHumidity

Continuous monitoring of Hum in the face mask using a RHT03 sensor, only in the experimental study arm

DIAGNOSTIC_TESTCardiopulmonary exercise testing

CPET using an ULTIMA CPX device (MGC Diagnostics, Saint Paul, MI, USA) with an ergometric bike (eBike, GE Healthcare, Wauwatosa, WI, USA). Participants will be asked to exercise (steady pedaling at 60 rpm) at 30% of their predicted maximum workload (Wmax) for 4 minutes, at 50% of Wmax for 2 minutes and at 70% of Wmax for 1 minute. Wmax will be calculated as 3 Watts/kg. CPET will be performed in both study arms

DIAGNOSTIC_TESTDiscomfort level

Discomfort assessment using a special scale graded from 1 to 10 (Fikenzer, 2020). Both study arms, after CPET.

Sponsors

University of Patras
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
OTHER
Masking
NONE

Intervention model description

Participants will be randomized to begin with Phase I followed by Phase II or Phase II followed by Phase I.

Eligibility

Sex/Gender
ALL
Age
8 Years to 14 Years
Healthy volunteers
Yes

Inclusion criteria

1. Children should not suffer from conditions that are likely to affect CPET outcomes, such as respiratory (asthma and chronic lung disease), cardiac (congenital heart disease, heart failure), neurologic and musculoskeletal disorders. 2. Height \>135 cm 3. Parental written informed consent

Exclusion criteria

1. Points #1 or #2 not fulfilled 2. Child not willing to participate (e.g. not willing to wear the sensors)

Design outcomes

Primary

MeasureTime frameDescription
SpO2Minute 1Oxygen saturation
HRMinute 1Heart rate
EtCO2Minute 1End-tidal CO2
RRMinute 1Respiratory rate
TemperatureMinute 1Air temperature (in degrees Celsius) within the face mask
HumidityMinute 1Relative air humidity (%) within the face mask
Discomfort levelMinute 7Level of discomfort (specific questionnaire (5 items), scale 1 to 10) after CPET
Exercise-induced bronchoconstrictionMinute 7% change in FEV1 value before-after CPET
% change in nPIFMinute 7% change in nPIF value before-after CPET

Contacts

Primary ContactSotirios Fouzas, Prof.
sfouzas@upatras.gr+30 6944510047
Backup ContactMichael Anthracopoulos, Prof.
manthra@otenet.gr+30 2610 999716

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026